Sandoz Group AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 65 Fair Values set on narratives written by author
CHF 66.74
18.88 (39.45%)
7.9% undervalued intrinsic discount
CHF 72.48
Fair Value
Price CHF 66.74
AnalystConsensusTarget CHF 72.48
AnalystLowTarget CHF 55.07
AnalystHighTarget CHF 81.99
Fair ValueCHF 72.48
Share Pricen/a
SDZ Community Narratives
AN
Fair Value
·Fair Value CHF 72.48 7.9% undervalued intrinsic discount
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
1users have liked this narrative
0users have commented on this narrative
38users have followed this narrative
AN
Fair Value
·Fair Value CHF 55.07 21.2% overvalued intrinsic discount
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value CHF 81.99 18.6% undervalued intrinsic discount
Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Sandoz Group
7.9% undervalued intrinsic discount
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
View narrativeAN
Updated 3 Sep
Sandoz Group
21.2% overvalued intrinsic discount
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
View narrativeAN
Updated 16 Aug
Sandoz Group
18.6% undervalued intrinsic discount
Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption
View narrativeAN
Updated 1 Apr
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
SDZ: Biosimilar Expansion And Margin Shift Will Guide Future P/E Profile
Fair Value: CHF 72.48 7.9% undervalued intrinsic discount
38 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SDZ: Brazil Diabetes Entry And Legal Settlements Will Still Restrain Earnings Multiple
Fair Value: CHF 55.07 21.2% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Fair Value: CHF 81.99 18.6% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sandoz Group AG Key Details
About SDZ
- Founded
- 1886
- Employees
- 20000
- CEO
- Website
View website
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.